Indian pharma maker of branded generics for India plus a large export API business, strong in anti-malarials and pain drugs.
Indian pharma maker of branded generics for India plus a large export API business, strong in anti-malarials and pain drugs.
Earns from two engines: branded medicines prescribed by Indian doctors and sold through pharmacies, and active ingredients sold in bulk to other drugmakers abroad, which it makes itself rather than buying in. Anti-malarial drugs sold into WHO-backed tenders are a niche line. It took control of Unichem Laboratories, another Indian drugmaker, in 2023.
In one line: India's API-heavy generics maker.
Moat: narrow (scale, process know-how). Large backward-integrated API capacity gives cost and supply advantages over pure formulators.
Headquarters: Mumbai, India · Founded: 1949 · Employees: 23,467
Size IPCA Laboratories (IPCALAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $5.03B, the 213th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,854 on 18 Nov 2026.
Performance Over six months the shares gained 11.9%, against +10.5% for the median peer and +3.8% for the India market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 12.0% over the last twelve months (peer median +11.4%); the operating margin is 18.4% (peer median 21.2%).
Valuation It trades at 31.1× forward earnings against a peer median of 25.8× (8th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.8 points above its cost of capital (9.4% WACC).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹105B | ₹95.6B | ₹88.5B | ₹76.1B | ₹62.0B |
| Revenue growth | — | +8% | +16% | +23% | — |
| Gross profit | ₹47.9B | ₹35.0B | ₹28.5B | ₹21.9B | ₹16.9B |
| EBITDA | ₹23.7B | ₹20.3B | ₹17.2B | ₹11.6B | ₹9.93B |
| Net income | ₹14.0B | ₹11.4B | ₹7.38B | ₹5.47B | ₹4.71B |
| Free cash flow | n/a | ₹4.42B | ₹5.00B | ₹4.83B | ₹3.26B |
| Capital expenditure | n/a | ₹6.56B | ₹7.76B | ₹4.11B | ₹4.94B |
| Total debt | ₹7.53B | ₹8.09B | ₹13.6B | ₹14.4B | ₹14.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| IPCA Laboratories IPCALAB.NS | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% |
| Divi's Laboratories DIVISLAB.NS | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% |
| Aurobindo Pharma AUROPHARMA.NS | $11.0B | +19% | +14% | 15% | 22.3× | 21.1% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% |
| Torrent Pharmaceuticals TORNTPHARM.NS | $18.8B | +3% | +42% | 22% | 70.2× | 37.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IPCALAB.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.2% | -1.2% | 9th highest of 21 |
| 6-month return | +11.9% | +10.5% | 7th highest of 21 |
| Distance from 52-week high | -9.0% | -24.4% | 6th highest of 21 |
| Revenue growth (TTM) | +12.0% | +11.4% | 10th highest of 19 |
| Operating margin | 18.4% | 21.2% | 8th lowest of 19 |
| Forward P/E | 31.1× | 25.8× | 8th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 16.5% | 5.8% | 5th most demanding of 17 |
| Growth delivered (Del g) | +12.2% | +13.0% | 8th lowest of 17 |
| Hurdle (Req g minus delivered) | +4.3 pp | -3.6 pp | 4th most demanding of 17 |
| ROIC minus cost of capital | +3.8 pp | +5.8 pp | 8th lowest of 17 |
| EV / EBITDA | 20.3× | 22.8× | 5th cheapest of 11 |
| Net debt / EBITDA | -0.1× | -0.8× | 4th most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.48B | -23% | +6% | 3% | 7.0× | 1.3% | +4.0% |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |